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Abstract
Introduction Ki-67 labeling index assessed by immunohistochemical assays has been shown useful in assessing the risk of 
recurrence for estrogen receptor (ER)-positive HER2-negative breast cancers (BC) and distinguishing Luminal A-like from 
Luminal B-like tumors. We aimed to assess the performance of the Ventana CONFIRM anti-Ki-67 (30-9) Rabbit Monoclonal 
Primary Antibody.
Methods We constructed a case–cohort design based on a random sample (n = 679) of all patients operated on for a first 
primary, non-metastatic, ER-positive, HER2-negative BC at the European Institute of Oncology (IEO) Milan, Italy during 
1998–2002 and all additional patients (n = 303) operated during the same period, who developed an event (metastasis in dis-
tant organs or death due to BC as primary event) and were not included in the previous subset. Multivariable Cox proportional 
hazards regression with inverse subcohort sampling probability weighting was used to evaluate the risk of event according to 
Ki-67 (30-9) and derived intrinsic molecular subtype, using previously defined cutoff values, i.e., respectively 14% and 20%.
Results Ki-67 was < 14% in 318 patients (32.4%), comprised between 14 and 19% in 245 patients (24.9%) and ≥ 20 in 419 
patients (42.7%). At multivariable analysis, the risk of developing distant disease was 1.88 (95% CI 1.20–2.93; P = 0.006) 
for those with Ki-67 comprised between 14 and 19%, and 3.06 (95% CI 1.93–4.84; P < 0.0001) for those with Ki-67 ≥ 20% 
compared to those with Ki-67 < 14%. Patients with Luminal B-like BC had an approximate twofold risk of developing dis-
tant disease (HR = 1.91; 95% CI 1.35–2.71; P = 0.0003) than patients with Luminal A-like BC defined using Ki-67 (30-9).
Conclusions Ki-67 evaluation using the 30-9 rabbit monoclonal primary antibody was able to stratify patients with ER-
positive HER2-negative BC into prognostically distinct groups. Ki-67 assessment, with strict adherence to the international 
recommendations, should be included among the clinically useful biological parameters for the best treatment of patients 
with BC.
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Introduction
Ki-67 is a nuclear antigen expressed by all proliferating 
cells during late G1 through the M phases of the cell cycle, 
peaking in the G2-M and with a rapid decline after mitosis 
[1]. Ki-67 labeling index assessed by immunohistochemical 
assays is a powerful prognostic marker in breast cancer. It 
is especially useful in assessing the risk of recurrence for 
estrogen receptor (ER)-positive HER2-negative breast can-
cers, where it may be considered a surrogate of the molecu-
lar assays for distinguishing Luminal A-like from Luminal 
B-like tumors [2]. Despite methodological problems still 
exist in the determination of Ki-67 in the routine clinical 
practice, both the Panellists of the St. Gallen Consensus [3] 
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and the European Group on Tumor Markers (EGTM) [4] 
have endorsed use of Ki-67 in combination with established 
prognostic factors for determining prognosis, especially if 
values are low (e.g. < 10% of immunostained tumor cells) 
or high (e.g. > 25% cell staining). The higher cutoff value is 
based on a meta-analysis showing that a threshold of > 25% 
cell staining was associated with a greater risk of death com-
pared with lower values [5].
The mouse monoclonal antibody MIB-1 was the first 
antibody to be raised against a formalin-resistant epitope 
of Ki-67, and it has been extensively used in both clinical 
research and routine practice [6].
We evaluated the performance of the CONFIRM anti-
Ki-67 (30-9) Rabbit Monoclonal Primary Antibody in 
assessing the risk of distant relapses in a large series of 
patients with ER-positive HER2-negative breast cancer 
treated and followed up in a single Institution.
Materials and methods
Patients selection
The initial cohort (9415 patients) comprised all women 
operated on for a first primary, non-metastatic, ER-positive 
HER2 negative, breast cancer (BC) at the European Insti-
tute of Oncology (IEO) Milan, Italy, who did not receive 
neoadjuvant treatment [7]. We subsequently restricted the 
cohort to 3986 patients operated on between 1998 and 
2002 and for whom long-term follow-up data were avail-
able. A case–cohort [8] was built by randomly selecting 
approximately 17% of the above cohort (n = 679). Additional 
patients (n = 303) who developed an event (metastasis in 
distant organs or death due to BC as primary events) were 
added to this cohort (Supplementary Fig. 1).
Laboratory methods
Ki-67 was evaluated using the VENTANA CONFIRM anti-
Ki-67 (30-9) Rabbit Monoclonal Primary Antibody (Ven-
tana Medical Systems, Inc., Tucson, AZ) using OptiView 
IHC DAB detection on the BenchMark ULTRA advanced 
staining platform. The stained slides were evaluated at the 
IEO by certified pathologists trained to score Ki-67 accord-
ing to the recommendations of the International Ki-67 in 
Breast Cancer Working Group [9].
Samples were retrieved from the Pathology archives with 
Institutional Review Board approval and classified as ‘Lumi-
nal A-like’; estrogen receptor (ER)-positive, HER2-negative 
tumors with “low” Ki-67 (< 14%) or with “intermediate” 
Ki-67 (14–19%) and “high” progesterone receptor expres-
sion (PgR ≥ 20%), and ‘Luminal B-like’; HER2 negative, 
tumors ER positive, HER2 negative, with “intermediate” 
Ki-67 (14–19%) and “low” PgR (< 20%) or with “high” 
Ki-67 (≥ 20%) [7] (Supplementary Table 1).
Statistical methods
Associations between clinicopathological characteristics and 
Ki-67 expression were evaluated with the Mantel–Haenszel 
test for trend. The main outcome was distant disease-free 
survival (DDFS) and was calculated from the date of sur-
gery to the date of any first event or the date of last contact 
with the patient. Distant disease was defined as the occur-
rence of metastasis in distant organs or death due to BC 
as primary events. The rate of events in the subcohort was 
calculated dividing the number of events recorded during 
follow-up by the total number of patient-years accumulated 
during the observation period and 95% confidence intervals 
calculated using the mid-P exact method. Cumulative inci-
dence curves were drawn for patients in the subcohort using 
the Kaplan–Meier method and difference between patient 
subgroups was assessed using the log-rank test. Multivari-
able Cox proportional hazards regression with inverse sub-
cohort sampling probability weighting was used to evaluate 
the risk of metastasis or death from BC across groups in the 
combined case–cohort [10, 11]. In the multivariable analy-
sis, Ki-67 was considered either as a continuous variable, 
expressing the hazard ratio (HR) for each 10% increase of 
Ki-67 labeling index or was categorized using the same cut-
off values used for the definition of surrogate BC molecular 
subtypes, i.e., respectively 14% and 20% [7]. Other variables 
considered in the multivariable analysis include menopausal 
status, pathological T (pT1, pT2, pT3/4), regional lymph 
node status (pN0, pN+), tumor grade (G1, G2, G3), peri-
tumoral vascular invasion (PVI) (absent, present), estrogen 
receptor (ER) and progesterone receptor (PgR) expression 
(< 20% vs. ≥ 20%) and adjuvant treatment (none, hormone 
therapy alone, or hormone therapy plus chemotherapy). 
Finally, restricted cubic spline Cox regression models were 
applied to assess dose–response relationships. Analyses 
were carried out with the SAS software (version 9.4, Cary 
NC). P values were two sided. P < 0.05 were considered sta-
tistically significant.
Results
The case–cohort comprised 982 patients (679 patients are 
part of the 1998–2002 subcohort (including 84 with event) 
and 303 are patients who developed event outside of the sub-
cohort (Supplementary Fig. 1). Of the 387 events, 10 were 
death from breast cancer as a first event, and the remain-
ing 377 were distant metastases, with a prevalence of bone 
metastases (155 events) followed by lung (46 events) and 
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liver metastases (44 events). Ninety-five patients developed 
multiple metastases as first event.
Distribution of Ki-67 according to clinicopathological 
characteristics is displayed in Table 1. Overall, the median 
Ki-67 expression was 18%, in 318 patients (32.4%) it was 
< 14%, in 245 patients (24.9%) it was comprised between 14 
and 19% and in 419 patients (42.7%) it was ≥ 20%. Distribu-
tion was significantly different across all subgroups evalu-
ated, Ki-67 expression being significantly higher in premen-
opausal women P = 0.0002), and being directly associated 
with pT, pN, tumor grade, presence of PVI, and inversely 
associated with the expression of ER and PgR receptors 
(P < 0.0001 for all the associations). Particularly elevated 
median Ki-67 expression (27%) was found in patients with 
poorly differentiated tumors and in patients with tumors 
showing low (1–19% immunoreactive tumor cells) or mod-
erate (20–49% immunoreactive tumor cells) ER expression, 
and with a median Ki-67 value of 35% and 27%, respec-
tively. Lowest median Ki-67 was observed in patients with 
well-differentiated tumors (median 9%).
In the subcohort, 84 patients developed distant disease or 
died from BC as first event during follow-up, correspond-
ing to an event rate of 1.60 per 100 patient-year (Table 2). 
The event rate increased from 0.61 per 100 patient-year for 
Table 1  Distribution of Ki-67 (30-9) according to selected clinicopathological characteristics
*P-value based on the Mantel–Haenszel Chi square test for trend
Patients Ki-67 (30-9)
Median (25th–75th) Mean Std. Dev < 14%
N (%)
14–19%
N (%)
≥ 20%
N (%)
P value*
All 982 18 (12–25) 19.6 ± 11.9 318 (100) 245 (100) 419 (100)
Menopausal status
 Pre/peri 434 19 (13–26) 21.2 ± 12.6 115 (36.2) 109 (44.5) 210 (50.1)
 Post 548 16 (11–24) 18.4 ± 11.1 203 (63.8) 136 (55.5) 209 (49.9) 0.0002
pT
 pT1 590 15 (10–22) 16.9 ± 10.2 245 (77.0) 160 (65.3) 185 (44.2)
 pT2 343 22 (16–29) 24.3 ± 13.4 61 (19.2) 72 (29.4) 210 (50.1)
 pT3/4 49 19 (14–25) 19.7 ± 8.5 12 (3.8) 13 (5.3) 24 (5.7) < 0.0001
pN
 pN0 459 16 (10–22) 17.7 ± 12.5 195 (61.3) 107 (43.7) 157 (37.5)
 1–3 Positive nodes 292 18 (13–25) 20.0 ± 11.2 81 (25.5) 86 (35.1) 125 (29.8)
 ≥ 4 Positive nodes 212 22 (16–29) 23.3 ± 10.2 35 (11.0) 48 (19.6) 129 (30.8) < 0.0001
 pNx 19 16 (7–25) 19.5 ± 14.5 7 (2.2) 4 (1.6) 8 (1.9)
Grade
 G1 181 9 (5–14) 10.5 ± 6.6 131 (41.2) 34 (13.9) 16 (3.8)
 G2 489 16 (12–21) 17.0 ± 8.0 169 (53.1) 170 (69.4) 150 (35.8)
 G3 286 27 (22–34) 30.1 ± 13.0 8 (2.5) 35 (14.3) 243 (58.0) < 0.0001
 Unknown 26 17 (10–24) 17.3 ± 7.8 10 (3.1) 6 (2.4) 10 (2.4)
PVI
 Absent 672 16 (10–23) 17.8 ± 11.3 263 (82.7) 169 (69.0) 240 (57.3)
 Present 310 22 (16–28) 23.5 ± 12.2 55 (17.3) 76 (31.0) 179 (42.7) < 0.0001
ER
 1–19% 17 35 (28–50) 38.7 ± 19.5 0 (0.0) 4 (1.6) 13 (3.1)
 20–49% 61 27 (17–30) 25.2 ± 13.0 13 (4.1) 12 (4.9) 36 (8.6)
 ≥ 50% 904 19 (12–27) 21.6 ± 13.5 305 (95.9) 229 (93.5) 370 (88.3) < 0.0001
PgR
 1–20% 309 21 (14–30) 23.2 ± 14.2 86 (27.0) 75 (30.6) 148 (35.3)
 20–49% 180 22 (14–29) 22.9 ± 13.3 52 (16.4) 38 (15.5) 90 (21.5)
≥ 50% 493 18 (12–26) 21.2 ± 13.6 180 (56.6) 132 (53.9) 181 (43.2) 0.001
Adjuvant treatment
 None 41 12 (6–19) 15.0 ± 13.3 25 (7.9) 6 (2.4) 10 (2.4)
 Hormone therapy 470 14 (10–21) 15.8 ± 9.4 217 (68.2) 119 (48.6) 134 (32.1)
 Chemotherapy 470 22 (16–29) 23.9 ± 12.5 76 (23.9) 120 (49.0) 274 (65.4) < 0.0001
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patients with low Ki-67 (< 14%), to 1.47 per 100 patient-
year for those with intermediate Ki-67 (14–19%) and to 3.12 
per 100 patient-year for those with Ki-67 ≥ 20%. The 10-year 
cumulative incidence of distant metastasis (or BC-related 
death as first event) according to categories of Ki-67 is 
shown in Fig. 1. The event rate was about constant over time 
in the three groups. At 5 years and 10 years, respectively, 
2.7% (95% CI 1.3–5.5) and 6.4% (95% CI 3.8–10.7) of 
patients with Ki-67 < 14% developed an event against 6.8% 
(95% CI 3.8–11.9) and 13.5% (95% CI 8.9–20.3) of those 
with intermediate Ki-67, and 15.2% (95% CI 11.0–20.8) and 
26.6% (95% CI 20.7–33.8) of those with high Ki-67.
Dose–response in the subcohort was further evaluated 
in a plot based on a restricted cubic spline Cox regression 
model (Fig. 2): the rate of events increased linearly with 
the increasing expression of Ki-67 for values comprised 
between 0 and 30%. Above this threshold, the rate of events 
increased only slightly, and was based on a small fraction 
of the patients (only 79 (12%) patients in the subcohort had 
Ki-67 ≥ 30%).
Table 2  Distribution of events 
and multivariable analysis
a Hazards ratio (HR and 95% confidence intervals (CI) obtained from Cox proportional Hazards regression 
with inverse subcohort sampling probability weighting as defined in Miettinen (1976) using the SAS macro 
CCREGRESSION provided by Kulathinal et al. (2007)
b Results of an alternative multivariable model with Ki-67 (30-9) set as a continuous variable shows 
HR = 1.25 (95% CI 1.08–1.44; P = 0.002) for a 10% increase Ki-67, adjusted for menopausal status, pT, 
pN, grade, PVI, ER, PgR and adjuvant therapy
Sub–cohort (n = 679) Additional 
cases 
(n = 303)
Case–cohort (n = 982)
Patients Events Event rate per 100 
patient-year (95% 
CI)
HR (95% CI)a P-value
Ki-67 (30-9)b
 < 14% 278 14 0.61 (0.35–1.00) 40 1.00
 14–19% 171 20 1.47 (0.92–2.23) 74 1.88 (1.20–2.93) 0.006
 ≥ 20% 230 50 3.12 (2.34–4.08) 189 3.06 (1.93–4.84) < 0.0001
Menopausal status
 Pre/peri 289 34 1.50 (1.05–2.07) 145 1.00
 Post 390 50 1.68 (1.26–2.20) 158 1.43 (0.82–2.49) 0.20
pT
 pT1 466 34 0.88 (0.62–1.22) 124 1.00
 pT2 191 44 3.51 (2.58–4.67) 152 1.75 (1.24–2.45) 0.001
 pT3/4 22 6 4.41 (1.79–9.18) 27 3.26 (1.66–6.39) 0.0006
pN
 pN0 378 18 0.57 (0.35–0.89) 81 1.00
 pN+ 402 64 3.22 (2.50–4.09) 121 1.86 (1.25–2.78) 0.002
Grade
 G1 166 6 0.42 (0.17–0.87) 15 1.00
 G2 343 36 1.36 (0.96–1.86) 146 1.90 (1.06–3.39) 0.03
 G3 151 40 3.91 (2.83–5.28) 135 2.43 (1.27–4.65) 0.008
PVI
 Absent 510 45 1.10 (0.81–1.46) 162 1.00
 Present 169 39 3.36 (2.42–4.55) 141 1.53 (1.11–2.12) 0.009
ER
 ≥ 20% 665 81 1.57 (1.26–1.94) 300 1.00
 < 20% 14 3 3.06 (0.78–8.33) 3 1.05 (0.43–2.61) 0.91
PgR
 ≥ 20% 474 53 1.45 (1.10–1.88) 199 1.00
 < 20% 205 31 1.95 (1.35–2.73) 104 1.01 (0.72–1.41) 0.98
Adjuvant treatment
 None 34 3 1.22 (0.31–3.33) 7 1.50 (0.61–3.69) 0.37
 Hormone therapy 382 20 0.64 (0.39–0.94) 88 1.00
 Chemotherapy 262 61 3.18 (2.45–4.06) 208 1.73 (1.11–2.69) 0.02
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In the case–cohort, including additional cases reported 
outside of the subcohort and after adjusting for other prog-
nostic factors (menopausal status, pT, pN, grade, PVI, ER, 
and PgR) and for the type of adjuvant treatment received, 
Ki-67 remained significantly associated with DDFS. 
The relative risk of developing distant disease was 1.88 
(95% CI 1.20–2.93; P = 0.006) for those with Ki-67 com-
prised between 14 and 19%, and 3.06 (95% CI 1.93–4.84; 
P < 0.0001) for those with Ki-67 ≥ 20% compared to those 
with Ki-67 < 14%. Other independent prognostic factors 
include pT, pN, tumor grade, PVI. Patients receiving chemo-
therapy were also at higher risk of events (Table 2).
We used previously published criteria for the definition 
of surrogate BC molecular subtype using Ki-67 (Supple-
mentary Table 1). In the subcohort, 400 (58.9%) patients 
were classified as having “luminal A-like” and 279 (41.1%) 
“luminal B-like” BC. The 5-year and 10-year cumulative 
incidence of distant metastasis (or BC-related death as first 
event) were respectively 4.2% (95% CI 2.6–6.8) and 8.2% 
(95% CI 5.7–11.9) in the Luminal A group and 13.2% (95% 
Fig. 1  Cumulative incidence of events in the subcohort (N = 679) and corresponding Hazards Ratios in the case–cohort (N = 982) according to 
Ki-67 (30-9) and derived intrinsic molecular subtype
Fig. 2  Event rate* in the 
subcohort and Hazard Ratio** 
for distant disease-free survival 
according to Ki-67 (HR set to 
1.00 for Ki-67 = 14%) in the 
case–cohort
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CI 9.6–17.9) and 24.5% (95% CI 19.4–30.8%) in the Lumi-
nal B group (log-rank P < 0.0001) (Fig. 1).
In the whole case–cohort, multivariable analysis con-
firmed statistically significant increased risk of events for 
women with “Luminal B-Like” BC compared to women 
with “Luminal A-Like“ BC (HR = 1.91; 95% CI 1.35–2.71; 
P = 0.0003), after adjustment for menopausal status, pT, pN, 
grade, PVI and adjuvant therapy (Table 3).
Discussion
Ki-67 labeling index is a clinically validated prognostic 
factor in early breast cancer. In the neoadjuvant setting, it 
predicts the likelihood of pathological complete response 
(pCR) to chemotherapy. Furthermore, Ki-67 in the residual 
tumor [12, 13], and changes of Ki-67 labeling index between 
primary and residual tumors are prognostic for long-term 
outcome [14, 15].
Decline of Ki-67 after few weeks of neoadjuvant endo-
crine therapy is correlated with a better long-term outcome 
of ER-positive HER2-negative disease [16] and Ki67 assess-
ment in the residual tumor after neoadjuvant endocrine treat-
ment is predictive of long-term outcome [17]. In the adju-
vant setting, Ki-67 is a prognostic marker for disease-free 
and overall survival independent of tumor stage [18, 19].
Despite its undisputed prognostic value, however, Ki-67 
labeling index per se is not predictive of the benefit of add-
ing chemotherapy to endocrine therapy in the treatment of 
patients with ER-positive HER2-negative early breast cancer 
[20]. To inform the choice of systemic treatment for these 
patients, Ki-67 labeling index should be used in combination 
with other parameters, including tumor grade and a quan-
titative evaluation of ER and progesterone receptor (PgR) 
expression [3]. This has also been endorsed by the updated 
guidelines from the European Group of Tumor Markers [4].
By using a similar multifactorial approach, we have pre-
viously proposed a surrogate immunohistochemical defini-
tion of Luminal A-like and Luminal B-like breast cancer 
[7] that could be helpful in tailoring the systemic treatment, 
especially when multiparameter molecular assays are not 
available.
Most of the aforementioned studies have been conducted 
using the MIB-1 monoclonal antibody to Ki-67. Here, we 
have shown that Ki-67 evaluation using the Ventana 30-9 
rabbit monoclonal primary antibody, was similarly able to 
stratify patients with ER-positive HER2-negative breast can-
cer into prognostically distinct groups. Ki-67 evaluation in 
this cohort enabled maximizing the number of patients clas-
sified as having ‘Luminal A-like’ intrinsic subtype for whom 
the use of cytotoxic drugs could be at large avoided. Indeed, 
400 (58.9%) patients in the subcohort were classified as hav-
ing “Luminal A-like” and 279 (41.1%) “Luminal B-like” 
BC. These figures are strikingly similar to those obtained 
by Cheang and colleagues [21] using a rabbit monoclonal 
antibody to Ki-67 (clone SP6) in a series of 2847 hormone 
receptor-positive breast carcinomas, and showing a 59% 
prevalence of Luminal A-like tumors. More recently, a study 
evaluating Ki-67 with the MIB-1 antibody in a series of 
4718 patients with hormone receptor-positive disease also 
found a prevalence of Luminal A-like tumors of 58.2% [22]. 
Currently, the scientific community is still concerned about a 
perceived lack of accuracy and reproducibility in the assess-
ment of Ki-67 in the clinical setting. Major steps toward a 
harmonization of Ki-67 scoring in breast cancer, however, 
have been already made [9, 23–25], and it may be predicted 
that Ki-67 assessment, with strict adherence to the interna-
tional recommendations, will ultimately be included among 
the clinically useful biological parameters for the best treat-
ment of patients with breast carcinoma.
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Table 3  Distribution of events 
and multivariable analysis
a Hazards ratio (HR and 95% confidence intervals (CI) obtained from multivariable Cox proportional Haz-
ards regression with inverse subcohort sampling probability weighting as defined in Miettinen (1976) using 
the SAS macro CCREGRESSION provided by Kulathinal et al. (2007), adjusted for menopausal status, pT, 
pN, grade, PVI and adjuvant therapy
Sub–cohort (n = 679) Additional 
cases 
(n = 303)
Case–cohort (n = 982)
Patients Events Event rate per 100 
patient-year (95% CI)
HR (95% CI)a P-value
Molecular subtype
Luminal A-like 400 27 0.83 (0.56–1.20) 88 1.00
Luminal B-like 279 57 2.84 (2.17–3.65) 215 1.91 (1.35–2.71) 0.0003
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